Literature DB >> 12240900

GH-IGF-I axis in non-obese women with functional hyperandrogenism.

M Legan1, A Kocijancic, J Prezelj, J Osredkar, S Fisker.   

Abstract

The study was conducted to assess the GH-IGF-I axis in non-obese women with functional hyperandrogenism (FH). Eighteen FH women aged 18-35 yr with a body weight within 20% of ideal body weight and 10 weight-matched controls were included in the study. Basal serum GH, GH-binding protein (GHBP), IGF-I, IGF-binding protein-3 (IGFBP-3) levels were determined as well as GH levels during GHRH stimulation. In addition, basal serum androgens [free T (FT), delta4 and DHEAS], insulin and glucose levels were determined. The group of non-obese patients with FH differed from controls in GHBP (1.21+/-0.37 vs 0.93+/-0.25 nmol/l; p<0.05) and androgen levels (FT: 8.0+/-3.2 vs 1.9+/-1.2 pmol/l, p<0.001; delta4: 10.5+/-3.2 vs 5.9+/-2.1 nmol/l, p<0.001; DHEAS: 9.3+/-3.0 vs 5.1+/-1.8 micromol/l, p<0.001). GH (r=0.365; p<0.05) and IGF-I (r=0.508, p<0.01) serum levels were significantly correlated to serum DHEAS levels in a combined group of patients and controls. Our results support the suggestion that the GH-IGF-I axis plays an important role in the evolution of hormonal and metabolic derangement in non-obese FH women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12240900     DOI: 10.1007/BF03345102

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

Review 1.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

2.  Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery.

Authors:  M Hermansson; R B Wickelgren; F Hammarqvist; R Bjarnason; I Wennström; J Wernerman; B Carlsson; L M Carlsson
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

Review 3.  Involvement of growth factors in the pathophysiology of polycystic ovary syndrome.

Authors:  R Homburg
Journal:  Gynecol Endocrinol       Date:  1998-12       Impact factor: 2.260

4.  Defects in beta-cell function in functional ovarian hyperandrogenism.

Authors:  N M O'Meara; J D Blackman; D A Ehrmann; R B Barnes; J B Jaspan; R L Rosenfield; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1993-05       Impact factor: 5.958

5.  Growth hormone secretion in premenopausal women before and after ovariectomy: effect of hormone replacement therapy.

Authors:  V De Leo; D Lanzetta; D D'Antona; S Danero
Journal:  Fertil Steril       Date:  1993-08       Impact factor: 7.329

6.  Immunohistochemical localization of growth hormone receptor in cyclic human ovaries.

Authors:  M Tamura; H Sasano; T Suzuki; T Fukaya; T Watanabe; H Aoki; H Nagura; A Yajima
Journal:  Hum Reprod       Date:  1994-12       Impact factor: 6.918

7.  Short-term modulation of the androgen milieu alters pulsatile, but not exercise- or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes.

Authors:  D A Fryburg; A Weltman; L A Jahn; J Y Weltman; E Samojlik; R L Hintz; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

Review 8.  Insulin as an effector of human ovarian and adrenal steroid metabolism.

Authors:  J E Nestler; J F Strauss
Journal:  Endocrinol Metab Clin North Am       Date:  1991-12       Impact factor: 4.741

9.  Effect of insulin-like growth factor I on steroidogenesis in cultured human granulosa cells.

Authors:  C Bergh; J H Olsson; T Hillensjö
Journal:  Acta Endocrinol (Copenh)       Date:  1991-08

Review 10.  Hormones and obesity.

Authors:  P G Kopelman
Journal:  Baillieres Clin Endocrinol Metab       Date:  1994-07
View more
  1 in total

1.  GH-binding protein is related to bone mineral density in non-obese androgenized women.

Authors:  M Legan; J Osredkar; S Fisker; A Kocijancic
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.